Clobetasol propionate cream 0.05% for corticosteroid-responsive skin conditions

Clobetasol propionate cream 0.05% is a super-high potency topical corticosteroid used to relieve inflammation and itching associated with corticosteroid-responsive skin disorders. It is intended for external skin application only and should be used with caution due to potential systemic absorption.

This cream is prescribed to treat inflammatory and pruritic symptoms of corticosteroid-responsive dermatoses in adults and pediatric patients 12 years and older. Treatment is limited to a maximum of 2 consecutive weeks and should not exceed 50 grams per week.

Clobetasol propionate 0.05%

Clobetasol propionate is a potent corticosteroid that works by reducing inflammation and itching. It is thought to act by inducing proteins called lipocortins that inhibit phospholipase A2, thereby decreasing the production of inflammatory mediators like prostaglandins and leukotrienes.

Apply a thin layer of clobetasol propionate cream to the affected skin areas twice daily. Rub in gently and completely. Treatment duration should not exceed 2 consecutive weeks, and total usage should not exceed 50 grams per week. If no improvement occurs within 2 weeks, medical reassessment is advised. Occlusive dressings should not be used with this cream.

Geriatric patients require no dosage adjustment based on available data.

Clobetasol propionate cream 0.05% is contraindicated in patients with known hypersensitivity to any of its components.

• Do not use on the face, groin, or axillae, or for rosacea or perioral dermatitis.
• Prolonged use can cause suppression of the hypothalamic-pituitary-adrenal (HPA) axis, potentially leading to glucocorticosteroid insufficiency after stopping treatment.
• Systemic absorption may cause Cushing syndrome, hyperglycemia, or glucosuria.
• Patients using large surface areas or occlusive dressings require monitoring for HPA axis suppression via ACTH stimulation, plasma cortisol, or urinary free cortisol tests.
• If HPA axis suppression occurs, discontinue or reduce usage or switch to a less potent corticosteroid. Supplementary systemic corticosteroids may be needed in some cases.
• Pediatric patients, especially under 12 years, are at higher risk of systemic effects and HPA suppression; usage is not recommended in this group.
• If irritation or allergic contact dermatitis develops, discontinue usage and treat accordingly.
• If skin infections occur, treat with appropriate antibacterial or antifungal agents and stop clobetasol cream until infection is controlled.

Common side effects include burning and stinging sensations (reported in about 1% of patients). Less frequent reactions include itching, skin atrophy, and skin cracking or fissuring.

Additional possible local side effects include dryness, acne-like eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infections, irritation, striae, and miliaria.

Cushing syndrome has been reported with prolonged use, especially in infants and adults.

Pregnancy

Clobetasol propionate is classified as Pregnancy Category C. Animal studies have shown teratogenic effects with systemic and dermal corticosteroids, including skeletal abnormalities and cleft palate at doses equal to or lower than the human topical dose. There are no adequate controlled studies in pregnant women; use only if potential benefits justify risks to the fetus.

Lactation

It is unknown if topically applied clobetasol is excreted in human milk; systemically administered corticosteroids appear in breast milk and may affect growth or corticosteroid production in infants. Exercise caution when administering to nursing women.

Excessive topical use may result in systemic corticosteroid effects due to absorption, including HPA axis suppression.

Store clobetasol propionate cream at 20° to 25°C (68° to 77°F), with permitted excursions between 15° to 30°C (59° to 86°F). Do not refrigerate.